3657 results for «445»
3657 results
Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX
21 May 2026 – From EuroPCR 2026
This session explores the challenges of managing high thrombus burden in patients with acute coronary syndromes (ACS), with a focus on precision aspiration thrombectomy using the CAT RX device. Through case-based examples, it provides practical insights into procedural techniques and examines the role of CAT RX...
Evolving bifurcation treatment practices: DCB, angio-based FFR and side branch optimisation
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the evolving landscape of bifurcation PCI, focusing on drug-coated balloon (DCB) strategies, angio-based fractional flow reserve (FFR) and side branch optimisation. It highlights how new evidence and physiology-guided tools are reshaping decision-making in this complex lesion subset.
Discussions include insights from the...
Artificial intelligence-driven precision therapy for TAVI: progress and practice in China
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the integration of artificial intelligence into precision therapy for TAVI in China, highlighting its growing role in procedural planning, optimisation and outcome prediction.
Through case-based discussion, it shows how AI-enabled tools can simulate valve deployment and visualise post-TAVR results, supporting more precise...
When less is better - Differentiated therapies to safely achieve TR 0-1+
19 May 2026 – From EuroPCR 2026
Therapeutic goals in tricuspid regurgitation are evolving, with increasing emphasis on achieving near-complete elimination of regurgitation (TR 0–1+) through differentiated transcatheter strategies.
This EuroPCR 2026 session explores how transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) can be used in a complementary way to reach...
Real world practice inspiring new evidence generation in structural heart
21 May 2026 – From EuroPCR 2026
This LIVE case session showcases real-world clinical practice driving new evidence in structural heart interventions, with a focus on TAVI. It features expert insights into pre-procedural imaging and sizing, treatment strategies, procedural techniques, and post-procedural management. The session also introduces the novel Myval Octapro+ transcatheter heart...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
Left main and complex bifurcation stenting
14 May 2024 – From EuroPCR 2024
Watch this session focused on a patient with distal left main stenosis to understand that the stepwise provisional side branch (SB) stenting strategy is the standard approach for most left main trifurcation lesions. Discover the importance of optical frequency domain imaging for strategy determination and bifurcation...
Left main and complex bifurcation stenting
21 May 2026 – From EuroPCR 2026
This focused session explores optimal strategies for treating left main and complex bifurcation coronary lesions, a setting that remains both anatomically and technically demanding.
It highlights the role of intracoronary imaging in refining procedural planning and optimising stenting strategy and technique. The discussion also reviews the mechanical...
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function
09 May 2023
EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025
EuroPCR 2026: Elixir Medical's DynamX® bioadaptor demonstrates significantly lower event rates than drug-eluting stent in long-term follow-up, including reduction in cardiovascular death
19 May 2026
Promising Safety and Efficacy Results for Supraflex Cruz in HBR Subset Analysis from FIRE Trial, with 1-Month DAPT
03 Nov 2023
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
Positive 3-year results from FIRE Trial demonstrate Supraflex Cruz’s safety and efficacy in elderly heart attack patients
26 Sep 2025
Elixir Medical’s DynamX Bioadaptor demonstrates significant improvement over contemporary drug-eluting stent in patients with acute coronary syndrome and complex lesion subsets after six months
28 Oct 2024
EuroPCR 2024: Late-breaking data demonstrate significant clinical advantage of Elixir Medical’s DynamX bioadaptor over standard-of-care drug-eluting stent at two years
14 May 2024
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
17 May 2023